Efficacy and safety of pitavastatins in patients with acute myocardial infarction

Livalo in Acute Myocardial Infarction Study (LAMIS) II

Young Joon Hong, Myung Ho Jeong, Jang Ho Bae, Seok Kyu Oh, Seung-Woon Rha, Seung Ho Hur, Sung Yun Lee, Sang Wook Kim, Kwang Soo Cha, In Ho Chae, Tae Hoon Ahn, Kee Sik Kim

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background/Aims: We evaluated the efficacy and safety and influence on glucose tolerance by different doses of pitavastatins in acute myocardial infarction (AMI) patients. Methods: Consecutive 1,101 AMI patients who were enrolled in Livalo in Acute Myocardial Infarction Study (LAMIS)-II were randomly assigned to receive either 2 mg of pitavastatin or 4 mg of pitavastatin orally per day. Primary efficacy endpoint was composite of cardiac death, nonfatal myocardial infarction, target-le-sion revascularization, and hospitalization for unstable angina, heart failure or arrhythmic events at 12-month. Results: There was no significant difference in primary efficacy endpoint between 2 mg and 4 mg groups (9.07% vs. 9.13%, p = 0.976). The degree of the reduction of low density lipoprotein cholesterol (LDL-C) was significantly greater in 4 mg group compared to 2 mg group from baseline to follow-up (–42.05 ± 32.73 mg/dL vs. –34.23 ± 31.66 mg/dL, p = 0.002). Fasting plasma glucose level was reduced significantly in both groups (–20.16 ± 54.49 mg/dL in 4 mg group and –24.45 ± 63.88 mg/dL in 2 mg group, p < 0.001 and p < 0.001, respectively) and there was no significant change of glycated hemoglobin in two groups from baseline to follow-up (–0.13% ± 1.21% in 4 mg group and –0.04% ± 1.10% in 2 mg group, p = 0.256 and p = 0.671, respectively). Conclusions: Although LDL-C was reduced more significantly by using 4 mg of pitavastatin compared to 2 mg of pitavastatin, the event rate was comparable without adverse effects on glucose tolerance in both groups in AMI patients who were enrolled in LAMIS-II.

Original languageEnglish
Pages (from-to)656-667
Number of pages12
JournalKorean Journal of Internal Medicine
Volume32
Issue number4
DOIs
Publication statusPublished - 2017 Jul 1

Fingerprint

Myocardial Infarction
Safety
Glucose
LDL Cholesterol
Unstable Angina
Glycosylated Hemoglobin A
pitavastatin
Fasting
Hospitalization
Heart Failure

Keywords

  • Atherosclerosis
  • Hydroxymethylglu-taryl-CoA reductase inhibitors
  • Lipids
  • Myocardial infarction

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Efficacy and safety of pitavastatins in patients with acute myocardial infarction : Livalo in Acute Myocardial Infarction Study (LAMIS) II. / Hong, Young Joon; Jeong, Myung Ho; Bae, Jang Ho; Oh, Seok Kyu; Rha, Seung-Woon; Hur, Seung Ho; Lee, Sung Yun; Kim, Sang Wook; Cha, Kwang Soo; Chae, In Ho; Ahn, Tae Hoon; Kim, Kee Sik.

In: Korean Journal of Internal Medicine, Vol. 32, No. 4, 01.07.2017, p. 656-667.

Research output: Contribution to journalArticle

Hong, Young Joon ; Jeong, Myung Ho ; Bae, Jang Ho ; Oh, Seok Kyu ; Rha, Seung-Woon ; Hur, Seung Ho ; Lee, Sung Yun ; Kim, Sang Wook ; Cha, Kwang Soo ; Chae, In Ho ; Ahn, Tae Hoon ; Kim, Kee Sik. / Efficacy and safety of pitavastatins in patients with acute myocardial infarction : Livalo in Acute Myocardial Infarction Study (LAMIS) II. In: Korean Journal of Internal Medicine. 2017 ; Vol. 32, No. 4. pp. 656-667.
@article{522b805af36342ccb6bbeb840afd18ed,
title = "Efficacy and safety of pitavastatins in patients with acute myocardial infarction: Livalo in Acute Myocardial Infarction Study (LAMIS) II",
abstract = "Background/Aims: We evaluated the efficacy and safety and influence on glucose tolerance by different doses of pitavastatins in acute myocardial infarction (AMI) patients. Methods: Consecutive 1,101 AMI patients who were enrolled in Livalo in Acute Myocardial Infarction Study (LAMIS)-II were randomly assigned to receive either 2 mg of pitavastatin or 4 mg of pitavastatin orally per day. Primary efficacy endpoint was composite of cardiac death, nonfatal myocardial infarction, target-le-sion revascularization, and hospitalization for unstable angina, heart failure or arrhythmic events at 12-month. Results: There was no significant difference in primary efficacy endpoint between 2 mg and 4 mg groups (9.07{\%} vs. 9.13{\%}, p = 0.976). The degree of the reduction of low density lipoprotein cholesterol (LDL-C) was significantly greater in 4 mg group compared to 2 mg group from baseline to follow-up (–42.05 ± 32.73 mg/dL vs. –34.23 ± 31.66 mg/dL, p = 0.002). Fasting plasma glucose level was reduced significantly in both groups (–20.16 ± 54.49 mg/dL in 4 mg group and –24.45 ± 63.88 mg/dL in 2 mg group, p < 0.001 and p < 0.001, respectively) and there was no significant change of glycated hemoglobin in two groups from baseline to follow-up (–0.13{\%} ± 1.21{\%} in 4 mg group and –0.04{\%} ± 1.10{\%} in 2 mg group, p = 0.256 and p = 0.671, respectively). Conclusions: Although LDL-C was reduced more significantly by using 4 mg of pitavastatin compared to 2 mg of pitavastatin, the event rate was comparable without adverse effects on glucose tolerance in both groups in AMI patients who were enrolled in LAMIS-II.",
keywords = "Atherosclerosis, Hydroxymethylglu-taryl-CoA reductase inhibitors, Lipids, Myocardial infarction",
author = "Hong, {Young Joon} and Jeong, {Myung Ho} and Bae, {Jang Ho} and Oh, {Seok Kyu} and Seung-Woon Rha and Hur, {Seung Ho} and Lee, {Sung Yun} and Kim, {Sang Wook} and Cha, {Kwang Soo} and Chae, {In Ho} and Ahn, {Tae Hoon} and Kim, {Kee Sik}",
year = "2017",
month = "7",
day = "1",
doi = "10.3904/kjim.2016.016",
language = "English",
volume = "32",
pages = "656--667",
journal = "Korean Journal of Internal Medicine",
issn = "0494-4712",
publisher = "Korean Association of Internal Medicine",
number = "4",

}

TY - JOUR

T1 - Efficacy and safety of pitavastatins in patients with acute myocardial infarction

T2 - Livalo in Acute Myocardial Infarction Study (LAMIS) II

AU - Hong, Young Joon

AU - Jeong, Myung Ho

AU - Bae, Jang Ho

AU - Oh, Seok Kyu

AU - Rha, Seung-Woon

AU - Hur, Seung Ho

AU - Lee, Sung Yun

AU - Kim, Sang Wook

AU - Cha, Kwang Soo

AU - Chae, In Ho

AU - Ahn, Tae Hoon

AU - Kim, Kee Sik

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Background/Aims: We evaluated the efficacy and safety and influence on glucose tolerance by different doses of pitavastatins in acute myocardial infarction (AMI) patients. Methods: Consecutive 1,101 AMI patients who were enrolled in Livalo in Acute Myocardial Infarction Study (LAMIS)-II were randomly assigned to receive either 2 mg of pitavastatin or 4 mg of pitavastatin orally per day. Primary efficacy endpoint was composite of cardiac death, nonfatal myocardial infarction, target-le-sion revascularization, and hospitalization for unstable angina, heart failure or arrhythmic events at 12-month. Results: There was no significant difference in primary efficacy endpoint between 2 mg and 4 mg groups (9.07% vs. 9.13%, p = 0.976). The degree of the reduction of low density lipoprotein cholesterol (LDL-C) was significantly greater in 4 mg group compared to 2 mg group from baseline to follow-up (–42.05 ± 32.73 mg/dL vs. –34.23 ± 31.66 mg/dL, p = 0.002). Fasting plasma glucose level was reduced significantly in both groups (–20.16 ± 54.49 mg/dL in 4 mg group and –24.45 ± 63.88 mg/dL in 2 mg group, p < 0.001 and p < 0.001, respectively) and there was no significant change of glycated hemoglobin in two groups from baseline to follow-up (–0.13% ± 1.21% in 4 mg group and –0.04% ± 1.10% in 2 mg group, p = 0.256 and p = 0.671, respectively). Conclusions: Although LDL-C was reduced more significantly by using 4 mg of pitavastatin compared to 2 mg of pitavastatin, the event rate was comparable without adverse effects on glucose tolerance in both groups in AMI patients who were enrolled in LAMIS-II.

AB - Background/Aims: We evaluated the efficacy and safety and influence on glucose tolerance by different doses of pitavastatins in acute myocardial infarction (AMI) patients. Methods: Consecutive 1,101 AMI patients who were enrolled in Livalo in Acute Myocardial Infarction Study (LAMIS)-II were randomly assigned to receive either 2 mg of pitavastatin or 4 mg of pitavastatin orally per day. Primary efficacy endpoint was composite of cardiac death, nonfatal myocardial infarction, target-le-sion revascularization, and hospitalization for unstable angina, heart failure or arrhythmic events at 12-month. Results: There was no significant difference in primary efficacy endpoint between 2 mg and 4 mg groups (9.07% vs. 9.13%, p = 0.976). The degree of the reduction of low density lipoprotein cholesterol (LDL-C) was significantly greater in 4 mg group compared to 2 mg group from baseline to follow-up (–42.05 ± 32.73 mg/dL vs. –34.23 ± 31.66 mg/dL, p = 0.002). Fasting plasma glucose level was reduced significantly in both groups (–20.16 ± 54.49 mg/dL in 4 mg group and –24.45 ± 63.88 mg/dL in 2 mg group, p < 0.001 and p < 0.001, respectively) and there was no significant change of glycated hemoglobin in two groups from baseline to follow-up (–0.13% ± 1.21% in 4 mg group and –0.04% ± 1.10% in 2 mg group, p = 0.256 and p = 0.671, respectively). Conclusions: Although LDL-C was reduced more significantly by using 4 mg of pitavastatin compared to 2 mg of pitavastatin, the event rate was comparable without adverse effects on glucose tolerance in both groups in AMI patients who were enrolled in LAMIS-II.

KW - Atherosclerosis

KW - Hydroxymethylglu-taryl-CoA reductase inhibitors

KW - Lipids

KW - Myocardial infarction

UR - http://www.scopus.com/inward/record.url?scp=85025157051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85025157051&partnerID=8YFLogxK

U2 - 10.3904/kjim.2016.016

DO - 10.3904/kjim.2016.016

M3 - Article

VL - 32

SP - 656

EP - 667

JO - Korean Journal of Internal Medicine

JF - Korean Journal of Internal Medicine

SN - 0494-4712

IS - 4

ER -